n/a.; n/d.
Introduction: The detection of early phases of neurodegenerative cognitive disorders is challenging. Differentiating these from non-neurodegenerative conditions is increasingly important, especially with the recent approval of disease-modifying treatments for early Alzheimer's in Europe (lceanemba and donanemba). This study aimed to identify the clinical profile of patients presenting for the first time at a ge...
Background: Several disease-modifying therapies (DMTs) have emerged in the last two decades for the treatment of multiple sclerosis (MS). The increasing use of these therapies has enhanced the need to study its impact on long-term disease progression and on the natural history of MS. This study aimed to characterize a Portuguese MS patient cohort in what concerns the natural history of disease by exploring diff...